Purpose

Phase IV, randomized, prospective, multi-center, open-label, comparison of transforming powder dressing to standard of care dressing for healing diabetic foot ulcers.

Condition

Eligibility

Eligible Ages
Between 18 Years and 89 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18-89 years old - Diagnosed with diabetes Mellitus; hemoglobin A1C < 12% - Diabetic foot ulcer present for minimum 30 days (Wagner grade 1 or 2 classification) - Wound drainage is minimal or moderate - No clinically active wound infection - Able and willing to provide consent - Has not participated in another research trial within 3 months of enrollment.

Exclusion Criteria

  • Unable to keep weekly research appointments - Unable or unwilling to use offloading device if recommended - Wounds with large amount (high) drainage - Active gangrene - Wounds impending surgical intervention (including revascularization or plastic surgery) - Untreated osteomyelitis - Soft tissue infection (can be enrolled once infection is cleared) - Active Charcot arthropathy - BMI >45kg/m2 - History of AIDS - History of organ transplant or impending transplant - End stage renal disease requiring dialysis - Decompensated hepatic or cardiac disease - Select autoimmune diseases - Lymphedema - Oral steroid use in last 3 months - Venous stasis disease - Active malignancy (cancer) - Unable to sign consent - Active alcohol or substance abuse - Pregnant or lactating women - Insufficient vascular flow to heal a wound - Hemoglobin A1C >12%

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Randomized, Prospective, Multi-Center, Open-Label, Comparison, Human, Interventional
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Transforming Powder Dressing
Half of the subjects will be randomized to Transforming Powder Dressing to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using Transforming Powder Dressing and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to other standard of care dressings used to treat diabetic foot ulcers.Surveys regarding pain and quality of life will be completed at each study visit.
  • Device: Transforming Powder Dressing
    Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.
    Other names:
    • Altrazeal
Active Comparator
Standard of Care Dressing
Half of the subjects will be randomized to receive standard of care wound dressings to treat their diabetic foot ulcers. Wounds will be evaluated weekly, debrided if needed, photographed, and measured. A wound dressing will be applied using standard of care wound products, and the wound will be offloaded when necessary (pressure taken off of the wound using a total contact cast or other device). Wound healing progress will be monitored and compared to transforming powder dressings used to treat diabetic foot ulcers. Surveys regarding pain and quality of life will be completed at each study visit.
  • Other: Standard of care topical wound agents and dressings
    Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.

Recruiting Locations

MedStar Georgetown University Hospital
Washington, District of Columbia 20007
Contact:
Theresa Moriarty, MSN
202-877-3657
Theresa.M.Moriarty@medstar.net

MedStar Washington Hospital Center
Washington, District of Columbia 20010
Contact:
Theresa Moriarty, MSN
202-877-3657
Theresa.M.Moriarty@medstar.net

MedStar Good Samaritan Hospital
Baltimore, Maryland 21230
Contact:
Terry Moriarty, MSN, CCRN
202-801-2420
Theresa.M.Moriarty@medstar.net

MedStar Franklin Square
Rossville, Maryland 21237
Contact:
Cynthia Yashinski
Cynthia.L.Yashinski@medstar.net

More Details

Status
Recruiting
Sponsor
ULURU Inc.

Study Contact

Vaidehi Shah, MBA
646-431-9455
vshah@altrazeal.com

Detailed Description

Diabetic men and women aged 18-89 years, who have a diabetic foot ulcer present for a minimum of 30 days will be considered for the study. Subjects will be randomized to either standard of care wound dressings or transforming powder dressing. Half of the subjects will receive standard of care dressings, and the other half will receive transforming powder dressing in a 1:1 randomization process at each of the study sites. Subjects will present to the study center weekly for up to 12 weeks (less time if the wound heals prior to 12 weeks). The last study visit occurs 12 weeks after the End of Study visit.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.